다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Frontiers in microbiology, v.10, 2019년, pp.336 -
Kelly, Ciaran Patrick (Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA , United States) , Chong Nguyen, Caroline (Inserm UMR1149, DHU Unity –) , Palmieri, Lola Jade (Paris Diderot University , Paris , France) , Pallav, Kumar (INSERM U1057, Université) , Dowd, Scot E. (Pierre et Marie Curie , Paris , France) , Humbert, Lydie (Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA , United States) , Seksik, Philippe (Molecular Research , Shalltower, TX , United States) , Bado, Andre (INSERM U1057, Université) , Coffin, Benoit (Pierre et Marie Curie , Paris , France) , Rainteau, Dominique (INSERM U1057, Université) , Kabbani, Toufic (Pierre et Marie Curie , Paris , France) , Duboc, Henri (Inserm UMR1149, DHU Unity –)
AI-Helper
Saccharomyces boulardii CNCM I-745 (SB) is a probiotic yeast used to lower the incidence of antibiotic-associated Clostridium difficile (C. difficile) infection, though its mechanism of action remains unclear. Cholic acid is a primary bile acid, which triggers the germination and promotes the growth...
Abou Chakra C. N. Pepin J. Sirard S. Valiquette L. ( 2014 ). Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 9 : e98400 . 10.1371/journal.pone.0098400 24897375
Allegretti J. R. Kearney S. Li N. Bogart E. Bullock K. Gerber G. K. ( 2016 ). Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment. Pharmacol. Ther. 43 1142 – 1153 . 10.1111/apt.13616 27086647
Buffie C. G. Bucci V. Stein R. R. McKenney P. T. Ling L. Gobourne A. ( 2015 ). Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517 205 – 208 . 10.1038/nature13828 25337874
Buffie C. G. Pamer E. G. ( 2013 ). Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13 790 – 801 . 10.1038/nri3535 24096337
Castagliuolo I. LaMont J. T. Nikulasson S. T. Pothoulakis C. ( 1996 ). Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect. Immun. 64 5225 – 5232 . 8945570
Chen X. Kokkotou E. G. Mustafa N. Bhaskar K. R. Sougioultzis S. O’Brien M. ( 2006 ). Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J. Biol. Chem. 281 24449 – 24454 . 10.1074/jbc.M605200200 16816386
De La Cochetière M. F. Durand T. Lepage P. Bourreille A. Galmiche J. P. Doré J. ( 2005 ). Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J. Clin. Microbiol. 43 5588 – 5592 . 10.1128/JCM.43.11.5588-5592.2005 16272491
Dethlefsen L. Huse S. Sogin M. L. Relman D. A. ( 2008 ). The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6 : e280 . 10.1371/journal.pbio.0060280 19018661
Duboc H. Rajca S. Rainteau D. Benarous D. Maubert M. A. Quervain E. ( 2013 ). Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62 531 – 539 . 10.1136/gutjnl-2012-302578 22993202
Francis M. B. Allen C. A. Shrestha R. Sorg J. A. ( 2013 ). Bile acid recognition by the clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog. 9 : e1003356 . 10.1371/journal.ppat.1003356 23675301
Fujimura K. E. Slusher N. A. Cabana M. D. Lynch S. V. ( 2010 ). Role of the gut microbiota in defining human health. Expert Rev. Anti Infect. Ther. 8 435 – 454 . 10.1586/eri.10.14 20377338
Hofmann A. F. ( 1999 ). Bile acids: the good, the bad, and the ugly. Physiology 14 24 – 29 . 10.1152/physiologyonline.1999.14.1.24 11390813
Humbert L. Maubert M. A. Wolf C. Duboc H. Mahé M. Farabos D. ( 2012 ). Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 899 135 – 145 . 10.1016/j.jchromb.2012.05.015 22664055
Jernberg C. Löfmark S. Edlund C. Jansson J. K. ( 2013 ). Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 7 56 – 66 . 10.1038/ismej.2012.91
Kabbani T. A. Pallav K. Dowd S. E. Villafuerte-Galvez J. Vanga R. R. Castillo N. E. ( 2016 ). Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes 8 17 – 32 . 10.1080/19490976.2016.1267890 27973989
Le Monnier A. Duburcq A. Zahar J. R. Corvec S. Guillard T. Cattoir V. ( 2015 ). Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J. Hosp. Infect. 91 117 – 122 . 10.1016/j.jhin.2015.06.017 26253518
Lessa F. C. Mu Y. Bamberg W. M. Beldavs Z. G. Dumyati G. K. Dunn J. R. ( 2015 ). Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372 825 – 834 . 10.1056/NEJMoa1408913 25714160
Levy A. R. Szabo S. M. Lozano-Ortega G. Lloyd-Smith E. Leung V. Lawrence R. ( 2015 ). Incidence and costs of clostridium difficile infections in Canada. Open Forum Infect. Dis. 2 : ofv076 . 10.1093/ofid/ofv076 26191534
McFarland L. V. ( 2006 ). Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101 812 – 822 . 10.1111/j.1572-0241.2006.00465.x 16635227
McFarland L. V. Surawicz C. M. Greenberg R. N. Fekety R. Elmer G. W. Moyer K. A. ( 1994 ). A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 271 1913 – 1918 . 10.1001/jama.1994.03510480037031 8201735
Neish A. S. ( 2009 ). Microbes in gastrointestinal health and disease. Gastroenterology 136 65 – 80 . 10.1053/j.gastro.2008.10.080 19026645
O’Brien J. A. Lahue B. J. Caro J. J. Davidson D. M. ( 2007 ). The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect. Control Hosp. Epidemiol. 28 1219 – 1227 . 10.1086/522676 17926270
Pozzoni P. Riva A. Bellatorre A. G. Amigoni M. Redaelli E. Ronchetti A. ( 2012 ). Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am. J. Gastroenterol. 107 922 – 931 . 10.1038/ajg.2012.56 22472744
Ridlon J. M. Kang D.-J. Hylemon P. B. ( 2006 ). Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47 241 – 259 . 10.1194/jlr.R500013-JLR200 16299351
Sorg J. A. Sonenshein A. L. ( 2008 ). Bile salts and glycine as cogerminants for Clostridium difficile spores. J. Bacteriol. 190 2505 – 2512 . 10.1128/JB.01765-07 18245298
Sorg J. A. Sonenshein A. L. ( 2010 ). Inhibiting the initiation of clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192 4983 – 4990 . 10.1128/JB.00610-10 20675492
Surawicz C. M. McFarland L. V. Greenberg R. N. Rubin M. Fekety R. Mulligan M. E. ( 2000 ). The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 31 1012 – 1017 . 10.1086/318130 11049785
Tasteyre A. Barc M.-C. Karjalainen T. Bourlioux P. Collignon A. ( 2002 ). Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii . Microb. Pathog. 32 219 – 225 . 10.1006/mpat.2002.0495 12071678
Theriot C. M. Koenigsknecht M. J. Carlson P. E. Jr. Hatton G. E. Nelson A. M. Li B. ( 2014 ). Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5 : 3114 . 10.1038/ncomms4114 24445449
van Nood E. Vrieze A. Nieuwdorp M. Fuentes S. Zoetendal E. G. de Vos W. M. ( 2013 ). Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368 407 – 415 . 10.1056/NEJMoa1205037 23323867
Weingarden A. R. Chen C. Bobr A. Yao D. Lu Y. Nelson V. M. ( 2014 ). Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am. J. Physiol. Gastrointest. Liver Physiol. 306 G310 – G319 . 10.1152/ajpgi.00282.2013 24284963
Weingarden A. R. Dosa P. I. DeWinter E. Steer C. J. Shaughnessy M. K. Johnson J. R. ( 2016 ). Changes in colonic bile acid composition following fecal microbiota transplantation are sufficient to control clostridium difficile germination and growth. PLoS One. 11 : e0147210 . 10.1371/journal.pone.0147210 26789728
Wilson K. H. Kennedy M. J. Fekety F. R. ( 1982 ). Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J. Clin. Microbiol. 15 443 – 446 . 7076817
Zoetendal E. G. Vaughan E. E. de Vos W. M. ( 2006 ). A microbial world within us. Mol. Microbiol. 59 1639 – 1650 . 10.1111/j.1365-2958.2006.05056.x 16553872
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.